News Quantified

AKTS – aktis oncology, inc. - common stock (US:NASDAQ)

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $34.00 price target on the stock.

Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.

Aktis Oncology (NASDAQ:AKTS) was upgraded by analysts at Wall Street Zen

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}